ACM-CpG injection for advanced solid tumors that responded to immunotherapy before
Part of Cancer clinical trials.
This trial tests a new injection, ACM-CpG, for people with advanced or metastatic solid tumors that previously responded to immunotherapy (with or without chemotherapy) but later grew again. The goal is to see if ACM-CpG can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years or older.
- You have advanced or metastatic solid tumor (stage 4) that has been confirmed by biopsy.
- You previously received immunotherapy (alone or with chemotherapy) and it shrank or stabilized your tumor, but now the disease has gotten worse.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within certain limits (doctors will check these).
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy that is injected directly into a tumor. The treatment uses mRNA (genetic material) wrapped in a fat particle to stimulate your immune system to attack the cancer. It's for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This trial is testing an experimental therapy (JCXH-211) that is injected directly into the tumor, combined with an immunotherapy drug (anti-PD-1 antibody). It is for people with advanced solid tumors who have not had success with standard treatments, and it aims to help the immune system fight the cancer more effectively.
This early-stage trial tests a new injection called CMTS1215 in people with solid tumors (cancers that form in organs or tissues) who have tried standard treatments without success. The goal is to see if CMTS1215 can help when other options haven't worked.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.